Rapport Therapeutics, Inc.(RAPP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RAPP Rapport Therapeutics, Inc.

交易中 07-09 10:51:34 EDT

41.93

-0.06

-0.15%

最高43.63	最低41.78	成交量7.27万
今开42.33	昨收41.99	日振幅4.41%
总市值19.98亿	流通市值13.32亿	总股本4,766万
成交额309.22万	换手率0.23%	流通股本3,177万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":41.925,"timestamp":1783608675162,"preClose":41.99,"halted":0,"volume":72708,"delay":0,"changeRate":-0.0015479876160991862,"floatShares":31772571,"shares":47661138,"eps":-2.560185,"marketStatus":"交易中","change":-0.065,"latestTime":"07-09 10:51:34 EDT","open":42.33,"high":43.63,"low":41.78,"amount":3092152.1442960002,"amplitude":0.044058,"askPrice":41.98,"askSize":199,"bidPrice":41.87,"bidSize":6,"shortable":3,"etf":0,"ttmEps":-2.560185,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1783627200000},"marketStatusCode":2,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":41.99,"preHourTrading":{"tag":"盘前","latestPrice":42.61,"preClose":41.99,"latestTime":"09:28 EDT","volume":1067,"amount":46095.300548,"timestamp":1783603680014,"change":0.62,"changeRate":0.014765,"amplitude":0.016432},"postHourTrading":{"tag":"盘后","latestPrice":42,"preClose":41.99,"latestTime":"19:51 EDT","volume":2973,"amount":124963.661,"timestamp":1783554665434,"change":0.01,"changeRate":0.000238,"amplitude":0.000238},"volumeRatio":0.647721,"impliedVol":0.6587,"impliedVolPercentile":0.3108},"requestUrl":"/m/hq/s/RAPP","defaultTab":"news","newsList":[{"id":"1104079350","title":"Leerink Partners 首予 Rapport Therapeutics 跑赢大盘评级，目标价52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104079350","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104079350?lang=zh_cn&edition=full","pubTime":"2026-06-24 18:08","pubTimestamp":1782295694,"startTime":"0","endTime":"0","summary":"Leerink Partners 发布研究报告，首次覆盖生物技术公司 Rapport Therapeutics, Inc.，并给予其“跑赢大盘”的评级。该投行为其设定的目标股价为每股52美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115191184","title":"Rapport Therapeutics在2026年美国神经病学学会年会公布Rap-219局灶性发作癫痫2a期随访结果 显示持续癫痫发作减少","url":"https://stock-news.laohu8.com/highlight/detail?id=1115191184","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115191184?lang=zh_cn&edition=full","pubTime":"2026-04-22 04:41","pubTimestamp":1776804073,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics公司在2026年美国神经病学学会年会上公布了其候选药物Rap-219针对局灶性发作癫痫的2a期临床试验随访期数据。研究结果显示，该药物在延长观察期内持续表现出显著的癫痫发作减少效果。\n此次公布的随访数据进一步验证了Rap-219在控制癫痫发作方面的持久疗效。临床试验参与者经过长期用药后，癫痫发作频率保持稳定下降趋势，这一发现为药物的长期安全性和有效性提供了重要证据。\n研究人员指出，持续性的癫痫控制效果对于改善患者生活质量具有重要意义。Rap-219在随访期间展现出的良好耐受性特征，也为后续更大规模的临床研究奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179109765","title":"Rapport Therapeutics与天纳西亚生物科技就Rap-219在大中华区的开发与商业化达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1179109765","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179109765?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:04","pubTimestamp":1773054297,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. 与天纳西亚生物科技公司今日共同宣布，双方已达成一项战略性合作协议，将携手推进创新药物Rap-219在大中华区（包括中国大陆、香港、澳门及台湾）的开发与商业化进程。此次合作旨在整合双方在研发、临床及市场拓展方面的优势资源，加速该疗法惠及广大患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167170585","title":"Tenacia获Rap-219在大中华区独家开发和商业化权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1167170585","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167170585?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:03","pubTimestamp":1773054230,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. 宣布，Tenacia公司已获得其候选药物Rap-219在大中华区（包括中国大陆、香港、澳门和台湾）的独家开发和商业化权利。此次授权合作将加速该疗法在亚太市场的布局，为当地患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157887434","title":"Rapport Therapeutics公司Rap-219三期临床试验计划将于2026年第二季度启动 中国设试验基地","url":"https://stock-news.laohu8.com/highlight/detail?id=1157887434","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157887434?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:03","pubTimestamp":1773054220,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics公司近日披露，其创新药物Rap-219的三期临床试验项目预计于2026年第二季度正式启动。值得关注的是，该全球临床试验网络将涵盖中国地区的多个研究中心，标志着中国在神经科学领域临床研究布局的重要性日益凸显。此次试验站点的拓展，不仅有助于加速患者招募进程，更将促进亚太地区前沿医疗资源的整合与共享。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105416410","title":"Rapport Therapeutics公司获2000万美元预付款，里程碑款项最高可达3.08亿美元，并享分层版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1105416410","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105416410?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:03","pubTimestamp":1773054204,"startTime":"0","endTime":"0","summary":"生物制药企业Rapport Therapeutics公司近日宣布达成一项重要合作协议。根据协议条款，该公司将获得2000万美元的预付款，并有资格获得最高可达3.08亿美元的里程碑款项。此外，协议还包含了基于产品销售业绩的分层版税安排。这一合作标志着Rapport Therapeutics在创新疗法开发领域取得了重大进展，为其未来的研发工作提供了坚实的资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131033553","title":"Rapport Therapeutics计划于2027年上半年启动RAP-219治疗PGTCs的三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1131033553","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131033553?lang=zh_cn&edition=full","pubTime":"2026-01-07 20:08","pubTimestamp":1767787738,"startTime":"0","endTime":"0","summary":"生物制药公司Rapport Therapeutics, Inc.近日披露重要研发进展，宣布将于2027年上半年正式启动其核心候选药物RAP-219针对原发性全身性强直阵挛发作的三期临床试验。这一关键性临床阶段的启动，标志着该药物在癫痫治疗领域的开发迈入决定性阶段。业界关注到，RAP-219作为一种创新疗法，其临床进展对满足PGTCs患者的未竟医疗需求具有重要意义。此次三期试验的启动计划，不仅体现了Rapport Therapeutics在神经科学领域的研发实力，也可能为癫痫治疗格局带来新的变革。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126656451","title":"Rapport Therapeutics 2024财年第四季度每股亏损$(0.57)，优于预期$(0.62)，年末现金、现金等价物和短期投资达3.053亿美元，预计可支持运营至2026年底","url":"https://stock-news.laohu8.com/highlight/detail?id=1126656451","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126656451?lang=zh_cn&edition=full","pubTime":"2025-03-11 19:43","pubTimestamp":1741693381,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics 报告季度每股亏损$，优于分析师预期的$，超出8.06%。与去年同期每股亏损$相比，这是一个92.88%的增长。以上内容来自Benzinga Earnings专栏，原文如下：Rapport $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 8.06 percent. This is a 92.88 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518274695","title":"Rapport Therapeutics, Inc.盘中异动 股价大跌5.24%报8.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518274695?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:00","pubTimestamp":1741615239,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时00分，Rapport Therapeutics, Inc.股票出现波动，股价急速下跌5.24%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为3087.26%、661.78%、287.22%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Impact Biomedical, Inc.，振幅分别为41.36%、40.24%、28.59%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220039abf3078d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220039abf3078d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RAPP","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517163165","title":"Rapport Therapeutics, Inc.盘中异动 快速跳水5.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517163165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517163165?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:31","pubTimestamp":1741271504,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时31分，Rapport Therapeutics, Inc.股票出现波动，股价快速下挫5.54%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.63%。其相关个股中，Plus Therapeutics, Inc.、Exicure, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为946.46%、104.14%、48.84%，振幅较大的相关个股有Plus Therapeutics, Inc.、Entero Therapeutics Inc.、Astria Therapeutics, Inc.，振幅分别为24.20%、13.05%、11.88%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223145abeb7784&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223145abeb7784&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","RAPP","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516340206","title":"Rapport Therapeutics, Inc.盘中异动 快速跳水5.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516340206","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516340206?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:31","pubTimestamp":1741012315,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时31分，Rapport Therapeutics, Inc.股票出现异动，股价急速跳水5.78%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为47.17%、23.41%、22.45%，振幅较大的相关个股有Entero Therapeutics Inc.、Cibus, Inc.、Galmed Pharmaceuticals Ltd.，振幅分别为11.70%、9.55%、9.35%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032231559637ac09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032231559637ac09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RAPP","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516937063","title":"Rapport Therapeutics, Inc.盘中异动 快速跳水5.03%报10.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516937063","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516937063?lang=zh_cn&edition=full","pubTime":"2025-03-01 02:06","pubTimestamp":1740765996,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日02时06分，Rapport Therapeutics, Inc.股票出现波动，股价急速下挫5.03%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.05%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301020636a2583559&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301020636a2583559&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RAPP","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514862502","title":"Rapport Therapeutics, Inc.盘中异动 股价大跌5.09%报11.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514862502","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514862502?lang=zh_cn&edition=full","pubTime":"2025-02-27 04:13","pubTimestamp":1740600826,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日04时13分，Rapport Therapeutics, Inc.股票出现波动，股价急速跳水5.09%。截至发稿，该股报11.18美元/股，成交量21.0055万股，换手率0.57%，振幅8.32%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.66%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270413469893e853&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270413469893e853&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","RAPP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514003019","title":"Rapport Therapeutics, Inc.盘中异动 快速下跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514003019","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514003019?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:23","pubTimestamp":1740500639,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时23分，Rapport Therapeutics, Inc.股票出现异动，股价快速下挫5.06%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.49%。其相关个股中，Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1331.76%、1114.37%、902.45%，振幅较大的相关个股有Organovo Holdings, Inc.、Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为224.93%、87.83%、66.67%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260023599892645f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260023599892645f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514708900","title":"Rapport Therapeutics, Inc.盘中异动 急速拉升5.52%报13.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514708900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514708900?lang=zh_cn&edition=full","pubTime":"2025-02-25 03:54","pubTimestamp":1740426886,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日03时54分，Rapport Therapeutics, Inc.股票出现波动，股价快速拉升5.52%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.17%。其相关个股中，Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 涨幅较大，Pepgen Inc.、Aditxt, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为324.89%、139.35%、40.20%，振幅较大的相关个股有Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 ，振幅分别为176.22%、162.04%、81.92%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225035446989134fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225035446989134fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","RAPP","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512353514","title":"Rapport Therapeutics, Inc.盘中异动 下午盘大幅下跌5.13%报13.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512353514","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512353514?lang=zh_cn&edition=full","pubTime":"2025-02-20 02:57","pubTimestamp":1739991465,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日02时57分，Rapport Therapeutics, Inc.股票出现波动，股价急速下跌5.13%。截至发稿，该股报13.32美元/股，成交量4.4918万股，换手率0.12%，振幅8.90%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.53%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220025745abd52e7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220025745abd52e7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512169270","title":"Rapport Therapeutics, Inc.盘中异动 股价大跌5.03%报15.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512169270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512169270?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:17","pubTimestamp":1739891876,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时17分，Rapport Therapeutics, Inc.股票出现波动，股价急速下挫5.03%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.79%。其相关个股中，Allogene Therapeutics, Inc.、Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为353.35%、135.13%、128.47%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Allogene Therapeutics, Inc.，振幅分别为148.75%、51.40%、50.49%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182317569627a049&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182317569627a049&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RAPP","LENZ","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511691391","title":"Rapport Therapeutics, Inc.盘中异动 股价大涨5.23%报16.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511691391","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511691391?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:55","pubTimestamp":1739544901,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时55分，Rapport Therapeutics, Inc.股票出现异动，股价大幅上涨5.23%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Moleculin Biotech, Inc.、Virpax Pharmaceuticals, Inc.、Cns Pharmaceuticals, Inc.涨幅较大，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为2034.72%、525.34%、439.22%，振幅较大的相关个股有Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Klotho Neurosciences, Inc.，振幅分别为66.93%、40.35%、33.28%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214225501962320e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214225501962320e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","RAPP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510359564","title":"Rapport Therapeutics, Inc.盘中异动 下午盘急速下挫5.05%报15.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510359564","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510359564?lang=zh_cn&edition=full","pubTime":"2025-02-12 03:16","pubTimestamp":1739301384,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日03时16分，Rapport Therapeutics, Inc.股票出现异动，股价快速下跌5.05%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.82%。其相关个股中，Omega Therapeutics, Inc.、Dermata Therapeutics Inc C/Wts 、Lipella Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为3114.20%、1474.72%、496.14%，振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为143.33%、72.23%、58.60%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120316249881eb04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120316249881eb04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","RAPP","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509723119","title":"Rapport Therapeutics, Inc.盘中异动 早盘股价大跌5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509723119","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509723119?lang=zh_cn&edition=full","pubTime":"2025-02-08 00:04","pubTimestamp":1738944296,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日00时04分，Rapport Therapeutics, Inc.股票出现波动，股价大幅下跌5.34%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.41%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208000456961b4986&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208000456961b4986&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rapportrx.com","stockEarnings":[{"period":"1week","weight":0.066},{"period":"1month","weight":0.1448},{"period":"3month","weight":0.2271},{"period":"6month","weight":0.4499},{"period":"1year","weight":2.3273},{"period":"ytd","weight":0.384}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0084},{"period":"3month","weight":0.0963},{"period":"6month","weight":0.074},{"period":"1year","weight":0.2016},{"period":"ytd","weight":0.0931}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Rapport Therapeutics, Inc.于2022年2月根据特拉华州法律注册成立，名称为Precision Neuroscience NewCo, Inc.，并于2022年10月更名为Rapport Therapeutics, Inc.。该公司是一家临床阶段的生物制药公司，专注于通过发现和开发用于中枢神经系统（“CNS”）疾病患者的转化小分子药物，成为精确神经科学的领导者。","exchange":"NASDAQ","name":"Rapport Therapeutics, Inc.","nameEN":"Rapport Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rapport Therapeutics, Inc.(RAPP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Rapport Therapeutics, Inc.(RAPP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Rapport Therapeutics, Inc.,RAPP,Rapport Therapeutics, Inc.股票,Rapport Therapeutics, Inc.股票老虎,Rapport Therapeutics, Inc.股票老虎国际,Rapport Therapeutics, Inc.行情,Rapport Therapeutics, Inc.股票行情,Rapport Therapeutics, Inc.股价,Rapport Therapeutics, Inc.股市,Rapport Therapeutics, Inc.股票价格,Rapport Therapeutics, Inc.股票交易,Rapport Therapeutics, Inc.股票购买,Rapport Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rapport Therapeutics, Inc.(RAPP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Rapport Therapeutics, Inc.(RAPP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}